Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
暂无分享,去创建一个
L. Rybicki | M. Kalaycio | B. Pohlman | E. Copelan | R. Sobecks | S. Andresen | R. Dean | J. Sweetenham | B. Bolwell | J. Waterman
[1] J. Cerhan,et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] O. Tournilhac,et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization , 2008, Leukemia.
[3] P. Gobbi,et al. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study , 2008, Haematologica.
[4] P. Chiusolo,et al. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre‐transplant therapy , 2007, Clinical transplantation.
[5] L. Rybicki,et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Mufti,et al. High incidence of therapy‐related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders , 2006, British journal of haematology.
[7] S. Pileri,et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Matthews,et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine , 2004, Leukemia.
[9] John M Bennett,et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Lois Shepherd,et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Kirchner,et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. , 2002, Blood.
[12] L. Rybicki,et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up , 2002, Bone Marrow Transplantation.
[13] W. Plunkett,et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] J. Mehta,et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma , 2000, British Journal of Cancer.
[15] M. Goormastic,et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma , 2000, Bone Marrow Transplantation.
[16] T. Lister,et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Martinelli,et al. Fludarabine‐containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients , 1999, British journal of haematology.
[18] B. Overmoyer,et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial , 1998, Bone Marrow Transplantation.
[19] P. Mclaughlin,et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[21] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[22] C. Tam,et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. , 2006, Haematologica.
[23] L. Lilly,et al. Liver transplantation for HBV and management of reinfection , 2005 .
[24] P. Feugier,et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. , 2004, Blood.
[25] U. Germing,et al. Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. , 2001, Leukemia research.